Cargando…
Low Concentrations of Metformin Selectively Inhibit CD133(+) Cell Proliferation in Pancreatic Cancer and Have Anticancer Action
Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States. The prognosis remains dismal with little advance in treatment. Metformin is a drug widely used for the treatment of type II diabetes. Recent epidemiologic data revealed that oral administration of metformin...
Autores principales: | Gou, Shanmiao, Cui, Pengfei, Li, Xiangsheng, Shi, Pengfei, Liu, Tao, Wang, Chunyou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648476/ https://www.ncbi.nlm.nih.gov/pubmed/23667692 http://dx.doi.org/10.1371/journal.pone.0063969 |
Ejemplares similares
-
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133(+) Cell Populations and Suppressing ERK/P70S6K Signaling
por: Chai, Xinqun, et al.
Publicado: (2015) -
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
por: Shi, Pengfei, et al.
Publicado: (2014) -
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
por: Li, Xiaogang, et al.
Publicado: (2017) -
Dendritic Cells Loaded with Pancreatic Cancer Stem Cells (CSCs) Lysates Induce Antitumor Immune Killing Effect In Vitro
por: Yin, Tao, et al.
Publicado: (2014) -
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3
por: Wang, Chunyou, et al.
Publicado: (2016)